MedTrace Logo

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

NCT01113580 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-11-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.

Conditions

Interventions

BIOLOGICAL

CSL's 2010/2011 Formulation of Enzira® Vaccine

45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0

Sponsors & Collaborators

  • Seqirus

    lead INDUSTRY

Principal Investigators

  • Ronnie Beboso, Dr · Chiltern (Early Phase) Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01113580 on ClinicalTrials.gov